Rating Rationale
January 21, 2020 | Mumbai
Rahu Health and Medical Tourism Private Limited
Rating Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.7 Crore
Long Term Rating CRISIL BBB+/Stable (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB+/Stable' rating on the long-term bank facilities of Rahu Health and Medical Tourism Private Limited (RHMT, part of the NM group).
 
The rating continues to reflect the established regional market position of the group the extensive experience of the promoters in the diagnostic services industry, strong financial risk profile because of low gearing and adequate debt protection metrics, and low working capital requirement. These strengths are partially offset by a moderate scale of operations, geographical concentration in revenue, and exposure to intense competition.

Analytical Approach

For arriving at the rating, CRISIL has combined the business and financial risk profiles of N Mohanlal and Company Private Limited (NMC) and RHMT. This is because the two companies, together referred to as the NM group, have common promoters, are in the same line of business, and have significant operational, managerial and financial linkages.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths
* Established regional market position and the extensive experience of the promoters in the diagnostic services industry: The NM group's track record of more than three decades in the diagnostic services industry has helped establish a strong market position in Mumbai. Furthermore, the group has continuously diversified the services it offers while also increasing tie-ups with hospitals and corporates and addition of new centres. This has led to steady growth in revenue to Rs 114.29 crore in fiscal 2019 from Rs 95.15 crore in fiscal 2015.
 
* Strong financial risk profile: The NM group's capital structure remains comfortable, with a gearing of 0.12 time and total outside liabilities to adjusted networth of 0.3 time as on March 31, 2019, on account of limited dependence on debt to fund capital expenditure (capex) and working capital requirement. The debt protection metrics are adequate, backed by healthy profitability and low debt, with net cash accrual to debt and interest coverage ratios of 2.30 times and 19.1 times, respectively, during fiscal 2019.  The financial profile is expected to remain at similar level on account of low dependence on debt.
 
* Low working capital requirement: Gross current assets (GCAs) were 27 days as on March 31, 2019, driven by predominantly cash-based sales, leading to debtors of 16 days. The group does not maintain a large inventory of consumables (inventory was 2 days) and also gets credit of 60 days from its suppliers.
 
Weaknesses
* Moderate scale of operations and geographical concentration: Despite NM group's established track record of operations and its strong regional presence, its market position is constrained by its moderate scale of operations, reflected in revenue of Rs 114.29 crore in fiscal 2019, in addition to a significant geographical concentration in revenue profile, as majority of its revenue is generated from the Mumbai region.
 
* Exposure to intense competition: The group faces competition from other large diagnostic players and hospitals, which have well-developed in-house diagnostic centres. This is also reflected in decline in operating margin from 22.3% in fiscal 2017 to 20.66% in fiscal 2019. The ability of the NM group to scale up the operations of its new centres and sustain healthy profitability will remain key rating sensitivity factors over the medium term.
Liquidity Adequate

Cash accruals are expected to be Rs 22-24 crore per annum in fiscals 2020 and 2021, against debt obligation of Rs 3.66 crore and Rs 1.14 crore, respectively. The bank limit of Rs 0.50 crore has remained unutilised, which provides cushion to liquidity. The cash and bank balance stood at Rs 16.56 crore as on March 31, 2019. The group is expected to undertake moderate capex, over the medium term, for expansion, which will be majorly funded through internal accruals. CRISIL expects internal accrual, cash and cash equivalent, and unutilised bank lines to be sufficient to meet its incremental working capital requirement and capex.

Outlook: Stable

CRISIL believes the NM group will continue to benefit over the medium term from its established regional market position in diagnostic services industry and healthy financial risk profile.
 
Rating sensitivity factors
Upward factors
*Sustained improvement in revenue by 20% by adding new centres (geographical diversification) and stable operating margin, leading to higher cash accruals
* Sustenance of financial and liquidity profile, while improving revenues.
 
Downward factors
*Decline in revenue or profitability declining to less than 15% -leading to lower accrual
*Large debt-funded capex weakening the financial risk profile.

About the Group

RHMT in 2004 and NMC was incorporated in 1977, in Mumbai. The group's operations are managed by Mr Nilesh Shah and Mr Rahil Shah. It offers diagnostic services including pathology, radiology, diagnostic cardiology, and preventive healthcare. It operates 11 centres in Mumbai, 4 in Pune, and 2 in Bengaluru, under the name of NM Medical.

Key Financial Indicators (Consolidated)
Particulars Unit 2019 2018
Revenue Rs crore 114.29 113.72
Profit After Tax (PAT) Rs crore 5.25 5.42
PAT Margin % 4.6 4.8
Adjusted Debt/Adjusted Networth Times 0.12 0.12
Interest coverage Times 19.07 16.93

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue
Size
(Rs.Cr)
Rating Assigned  with Outlook
NA Proposed Long Term Bank Loan Facility NA NA NA 0.6 CRISIL BBB+/Stable
NA Term Loan NA NA Mar-2024 6.4 CRISIL BBB+/Stable
 
Annexure - List of entities consolidated
Names of Entities Consolidated Extent of Consolidation Rationale for Consolidation
N Mohanlal and Company Private Limited Full Both the entities have common promoters, are in the same line of business, and have significant operational, managerial and financial linkages
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  7.00  CRISIL BBB+/Stable      13-02-19  CRISIL BBB+/Stable  01-03-18  CRISIL BBB+/Stable      CRISIL BBB+/Stable 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Proposed Long Term Bank Loan Facility .6 CRISIL BBB+/Stable Term Loan 7 CRISIL BBB+/Stable
Term Loan 6.4 CRISIL BBB+/Stable -- 0 --
Total 7 -- Total 7 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Criteria for rating entities belonging to homogenous groups

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Swapnali Mane
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 1856
Swapnali.Mane@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL